For Biotherapeutics, Innovation is Not Enough - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

For Biotherapeutics, Innovation is Not Enough
Biotech firms must first close the gaps between science and biology on the path toward QbD.


Pharmaceutical Technology
Volume 33, Issue 8, pp. 13


Maribel Rios
Even if one understood little about the development of biologics, last month's congressional testimonies regarding data exclusivity periods brought home a fundamental point: the complexity of biologics processing presents unique challenges not found in small-molecule manufacture. As further evidence, at the AAPS National Biotech Conference, the emphasis was on innovation, with the critical first step being the true understanding of the molecule, as plenary speaker Jim Thomas, Amgen's vice-president of process and product development stated.

This understading would help define critical quality attributes as the biotech industry begins its discussion toward incorporating the principles of quality by design (QbD), taking cues from the lessons learned in small-molecule production. As the meeting progressed, however, the talk in the halls and in meeting rooms focused on a major obstacle: How does industry link molecular structure and other attributes with biology and therapeutic effect?

The behavior of a biologic can be difficult to explain, let alone predict. One hot-topic problem discussed was the presence of agglomerates, particulates, and subvisible particles in a formulation. These particles may (and may not) cause opalescense and phase separation, but so too could mechanical stress, temperature, and pH, as Mary Cromwell (Genentech) explained. Whether, then, immunogenicity is altered is a huge question. For now, until science bridges the gaps, we must settle for Wim Jiscoot's (Leiden University) reply: "We simply don't know."

Maribel Rios is a senior editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here